# Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

> **NCT06549231** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Tours** · enrollment: 102 (estimated)

## Conditions studied

- Interstitial Lung Disease With Systemic Sclerosis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06549231
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2028-05-15
- **Final completion:** 2028-11-15
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549231, "Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06549231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*